

REFERENCES

1. Richelson E: Receptor pharmacology of neuroleptics: relation to clinical effects. *J Clin Psychiatry* 60 (Suppl 10): 5, 1999. [PMID: 10340682]
2. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 27: 1159, 2003. [PMID: 14642974]
3. Trenton A, Currier G, Zwemer F: Fatalities associated with therapeutic use and overdose of atypical antipsychotics. *CNS Drugs* 17: 307, 2003. [PMID: 12665390]
4. Page CB, Calver LA, Isbister GK: Risperidone overdose causes extrapyramidal effects but not cardiac toxicity. *J Clin Psychopharmacol* 30: 387, 2010. [PMID: 20631557]
5. Levine M, Ruha AM: Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. *CNS Drugs* 26: 601, 2012. [PMID: 22668123]
6. Minns AB, Clark RF: Toxicology and overdose of atypical antipsychotics. *J Emerg Med* 43: 906, 2012. [PMID: 22555052]
7. Tan HH, Hoppe J, Heard K: A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. *Am J Emerg Med* 27: 607, 2009. [PMID: 19497468]
8. Rauber-Lüthy C, Hofer KE, Bodmer M, et al: Gastric pharmacobezoars in quetiapine extended-release overdose: a case series. *Clin Toxicol (Phila)* 51: 937, 2013. [PMID: 24199644]
9. Miura N, Saito T, Taira T, Umebachi R, Inokuchi S: Risk factors for QT prolongation associated with acute psychotropic drug overdose. *Am J Emerg Med* 33: 142, 2015. [PMID: 25445869]
10. Isbister GK, Balit CR, Macleod D, Duffull SB: Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. *J Clin Psychopharmacol* 30: 391, 2010. [PMID: 20531221]
11. Nielsen J, Graff C, Kanters JK, et al: Assessing QT interval prolongation and its associated risks with antipsychotics. *CNS Drugs* 25: 473, 2011. [PMID: 21649448]
12. Joy JP, Coulter CV, Duffull SB, Isbister GK: Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses. *Clin Pharmacol Ther* 90: 243, 2011. [PMID: 21716272]
13. Gupta A, Lawrence AT, Krishnan K, et al: Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. *Am Heart J* 153: 891, 2007. [PMID: 17540188]
14. Yurthu BS, Hancı V, Güç A, Turan IO: Intravenous lipid infusion restores consciousness associated with olanzapine overdose. *Anesth Analg* 114: 914, 2012. [PMID: 22434897]
15. Arslan ED, Demir A, Yilmaz F, Kavalci C, Karakilic E, Çelikel E: Treatment of quetiapine overdose with intravenous lipid emulsion. *Keio J Med* 62: 53, 2013. [PMID: 23708294]
16. Bartos M, Knudsen K: Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine. *Clin Toxicol (Phila)* 51: 501, 2013. [PMID: 23768031]
17. Cobaugh DJ, Erdman AR, Booze LL, et al: Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. *Clin Toxicol (Phila)* 45: 918, 2007. [PMID: 18163235]
18. Zemrak WR, Kenna GA: Association of antipsychotic and antidepressant drugs with QT interval prolongation. *Am J Health Syst Pharm* 65: 1029, 2008. [PMID: 18499875]
19. Thronson LR, Pagalilauan GL: Psychopharmacology. *Med Clin North Am* 98: 927, 2014. [PMID: 25134867]
20. Cortese L, Pourcher-Bouchard E, Williams R: Assessment and management of antipsychotic-induced adverse events. *Can J Psychiatry* 43 (Suppl 1): 15S, 1998. [PMID: 9773233]
21. Pierre JM: Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. *Drug Saf* 28: 191, 2005. [PMID: 15733025]
22. Iqbal N, Lambert T, Masand P: Akathisia: problem of history or concern of today. *CNS Spectr* 12 (9 Suppl 14): 1, 2007. [PMID: 17805218]
23. Ramaswamy K, Masand PS, Nasrallah HA: Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry* 18: 183, 2006. [PMID: 16923657]
24. Erickson SC, Le L, Zakharyan A, et al: New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. *J Am Geriatr Soc* 60: 474, 2012. [PMID: 22288652]
25. Lipscombe LL, Lévesque LE, Gruneir A, et al: Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. *Am J Geriatr Psychiatry* 19: 1026, 2011. [PMID: 22123274]
26. Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ: Atypical antipsychotics and diabetic ketoacidosis: a review. *Psychopharmacology (Berl)* 226: 1, 2013. [PMID: 23344556]
27. Galling B, Correll CU: Do antipsychotics increase diabetes risk in children and adolescents? *Expert Opin Drug Saf* 5: 1, 2014. [PMID: 25480466]
28. Deng C: Effects of antipsychotic medications on appetite, weight, and insulin resistance. *Endocrinol Metab Clin North Am* 42: 245, 2013. [PMID: 24011886]
29. Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. *Pharmacotherapy* 29: 64, 2009. [PMID: 19113797]
30. Sedky K, Lippmann S: Psychotropic medications and leukopenia. *Curr Drug Targets* 7: 1191, 2006. [PMID: 17017894]
31. Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. *Hum Psychopharmacol* 23 (Suppl 1): 15, 2008. [PMID: 18098213]
32. Hedges D, Jeppson K, Whitehead P: Antipsychotic medication and seizures: a review. *Drugs Today (Barc)* 39: 551, 2003. [PMID: 12973403]
33. Lertxundi U, Hernandez R, Medrano J, et al: Antipsychotics and seizures: higher risk with atypicals. *Seizure* 22: 141, 2013. [PMID: 23146619]
34. Strawn JR, Keck PE, Caroff SN: Neuroleptic malignant syndrome. *Am J Psychiatry* 164: 870, 2007. [PMID: 17541044]
35. Berman BD: Neuroleptic malignant syndrome: a review for neurohospitalists. *Neurohospitalist* 1: 41, 2011. [PMID: 23983836]
36. Croarkin PE, Emslie GJ, Mayes T: Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. *J Clin Psychiatry* 69: 1157, 2008. [PMID: 18572981]
37. Trollor JN, Chen X, Sachdev PS: Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. *CNS Drugs* 23: 477, 2009. [PMID: 19480467]
38. Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. *J Clin Psychiatry* 72: 1222, 2011. [PMID: 21733489]
39. Perry PJ, Wilborn CA: Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. *Ann Clin Psychiatry* 24: 155, 2012. [PMID: 22563571]
40. Paden MS, Franjic L, Halcomb SE: Hyperthermia caused by drug interactions and adverse reactions. *Emerg Med Clin North Am* 31: 1035, 2013. [PMID: 24176477]
41. Musselman ME, Saely S: Diagnosis and treatment of drug-induced hyperthermia. *Am J Health Syst Pharm* 70: 34, 2013. [PMID: 23261898]
42. Neuhut R, Lindenmayer JP, Silva R: Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. *J Child Adolesc Psychopharmacol* 19: 415, 2009. [PMID: 19702493]